148 related articles for article (PubMed ID: 35610365)
1. Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.
Nair-Shalliker V; Bang A; Egger S; Yu XQ; Chiam K; Steinberg J; Patel MI; Banks E; O'Connell DL; Armstrong BK; Smith DP
Br J Cancer; 2022 Sep; 127(4):735-746. PubMed ID: 35610365
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous melanoma, prostate-specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and Up Study.
Egger S; Smith DP; Patel MI; Kimlin MG; Armstrong BK; Nair-Shalliker V
Br J Cancer; 2023 Jan; 128(1):71-79. PubMed ID: 36319848
[TBL] [Abstract][Full Text] [Related]
3. BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS).
Boehm K; Valdivieso R; Meskawi M; Larcher A; Sun M; Sosa J; Blanc-Lapierre A; Weiss D; Graefen M; Saad F; Parent MÉ; Karakiewicz PI
World J Urol; 2015 Dec; 33(12):2063-9. PubMed ID: 25824539
[TBL] [Abstract][Full Text] [Related]
4. Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia.
Negri E; Pelucchi C; Talamini R; Montella M; Gallus S; Bosetti C; Franceschi S; La Vecchia C
Int J Cancer; 2005 Apr; 114(4):648-52. PubMed ID: 15578689
[TBL] [Abstract][Full Text] [Related]
5. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
[TBL] [Abstract][Full Text] [Related]
6. Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
Kuo YJ; Sung FC; Hsieh PF; Chang HP; Wu KL; Wu HC
Cancer Med; 2019 May; 8(5):2514-2523. PubMed ID: 30968600
[TBL] [Abstract][Full Text] [Related]
7. [The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
Hanai T; Matsumoto S; Shouji S; Usui Y; Tang XY; Kato Y; Iguchi M; Uemura H; Terachi T
Hinyokika Kiyo; 2009 Apr; 55(4):187-91. PubMed ID: 19462822
[TBL] [Abstract][Full Text] [Related]
8. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
9. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
[TBL] [Abstract][Full Text] [Related]
10. Characteristics Associated with the Use of Diagnostic Prostate Biopsy and Biopsy Outcomes in Australian Men.
Chiam K; Bang A; Patel MI; Nair-Shalliker V; O'Connell DL; Smith DP
Cancer Epidemiol Biomarkers Prev; 2021 Sep; 30(9):1735-1743. PubMed ID: 34155065
[TBL] [Abstract][Full Text] [Related]
11. Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study.
Nørgaard M; Darvalics B; Thomsen RW
BMJ Open; 2020 Dec; 10(12):e041875. PubMed ID: 33371039
[TBL] [Abstract][Full Text] [Related]
12. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.
Tseng CH
BMC Cancer; 2013 Jan; 13():7. PubMed ID: 23286275
[TBL] [Abstract][Full Text] [Related]
13. Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case--control study in Wayne County, Michigan.
Patel DA; Bock CH; Schwartz K; Wenzlaff AS; Demers RY; Severson RK
Cancer Causes Control; 2005 Apr; 16(3):263-73. PubMed ID: 15947878
[TBL] [Abstract][Full Text] [Related]
14. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
[TBL] [Abstract][Full Text] [Related]
15. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia.
Khan S; Wolin KY; Pakpahan R; Grubb RL; Colditz GA; Ragard L; Mabie J; Breyer BN; Andriole GL; Sutcliffe S
BMC Urol; 2021 Mar; 21(1):47. PubMed ID: 33773592
[TBL] [Abstract][Full Text] [Related]
16. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.
Meigs JB; Barry MJ; Oesterling JE; Jacobsen SJ
J Gen Intern Med; 1996 Sep; 11(9):505-12. PubMed ID: 8905498
[TBL] [Abstract][Full Text] [Related]
17. The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea.
Hong Y; Lee S; Won S
PLoS One; 2019; 14(7):e0219394. PubMed ID: 31323022
[TBL] [Abstract][Full Text] [Related]
18. Metformin use and prostate cancer risk.
Preston MA; Riis AH; Ehrenstein V; Breau RH; Batista JL; Olumi AF; Mucci LA; Adami HO; Sørensen HT
Eur Urol; 2014 Dec; 66(6):1012-20. PubMed ID: 24857538
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.
Meigs JB; Mohr B; Barry MJ; Collins MM; McKinlay JB
J Clin Epidemiol; 2001 Sep; 54(9):935-44. PubMed ID: 11520654
[TBL] [Abstract][Full Text] [Related]
20. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
